Session » 4M096: Spondyloarthritis Including Psoriatic Arthritis – Clinical III: Miscellaneous (1818–1823)

Date: Monday, November 11, 2019

Time: 2:30PM-4:00PM

Meeting: 2019 ACR/ARP Annual Meeting

Abstract Number: 1818

Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study

Abstract Number: 1819

The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosing Spondylitis Disease Activity Index

Abstract Number: 1820

Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient

Abstract Number: 1821

Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain

Abstract Number: 1822

6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network

Abstract Number: 1823

Magnetic Resonance Enterography as a Screening Tool to Detect Sacroiliitis in Crohn’s Disease: Association with Clinical and Endoscopic Markers of Crohn’s Disease Activity

« View all sessions from this meeting